Quince Therapeutics Inc.

NASDAQ: QNCX · Real-Time Price · USD
1.10
0.01 (0.92%)
At close: May 23, 2025, 3:59 PM
1.10
0.00%
After-hours: May 23, 2025, 05:04 PM EDT

Quince Therapeutics Statistics

Share Statistics

Quince Therapeutics has 45.47M shares outstanding. The number of shares has increased by 1.82% in one year.

Shares Outstanding 45.47M
Shares Change (YoY) 1.82%
Shares Change (QoQ) 0%
Owned by Institutions (%) n/a
Shares Floating n/a
Failed to Deliver (FTD) Shares 113
FTD / Avg. Volume 0.04%

Short Selling Information

The latest short interest is 1.06M, so 2.39% of the outstanding shares have been sold short.

Short Interest 1.06M
Short % of Shares Out 2.39%
Short % of Float 2.75%
Short Ratio (days to cover) 9.37

Valuation Ratios

The PE ratio is -1.42 and the forward PE ratio is -1.51. Quince Therapeutics's PEG ratio is -0.03.

PE Ratio -1.42
Forward PE -1.51
PS Ratio 0
Forward PS 0.2
PB Ratio 2.68
P/FCF Ratio -2.52
PEG Ratio -0.03
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Quince Therapeutics.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 6.05, with a Debt / Equity ratio of 0.49.

Current Ratio 6.05
Quick Ratio 6.05
Debt / Equity 0.49
Debt / EBITDA -0.26
Debt / FCF -0.46
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee n/a
Profits Per Employee $-1,578,555.56
Employee Count 36
Asset Turnover 0
Inventory Turnover n/a

Taxes

Income Tax 87K
Effective Tax Rate -0.15%

Stock Price Statistics

The stock price has increased by 25.29% in the last 52 weeks. The beta is 0.83, so Quince Therapeutics's price volatility has been higher than the market average.

Beta 0.83
52-Week Price Change 25.29%
50-Day Moving Average 1.14
200-Day Moving Average 1.27
Relative Strength Index (RSI) 54.35
Average Volume (20 Days) 277,850

Income Statement

Revenue n/a
Gross Profit n/a
Operating Income -57.28M
Net Income -56.83M
EBITDA -56.55M
EBIT -56.74M
Earnings Per Share (EPS) -1.31
Full Income Statement

Balance Sheet

The company has 6.21M in cash and 14.81M in debt, giving a net cash position of -8.6M.

Cash & Cash Equivalents 6.21M
Total Debt 14.81M
Net Cash -8.6M
Retained Earnings -376.47M
Total Assets 107.09M
Working Capital 25.47M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -31.9M and capital expenditures -257K, giving a free cash flow of -32.16M.

Operating Cash Flow -31.9M
Capital Expenditures -257K
Free Cash Flow -32.16M
FCF Per Share -0.74
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

QNCX does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for QNCX is $9.5, which is 771.6% higher than the current price. The consensus rating is "Buy".

Price Target $9.5
Price Target Difference 771.6%
Analyst Consensus Buy
Analyst Count 6
Stock Forecasts

Scores

Altman Z-Score -5.85
Piotroski F-Score 2